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Abstract. Recent advances in neuroimaging and cerebrospinal fluid (CSF) biomarker assays have provided evidence of a
long preclinical stage of Alzheimer’s disease (AD). This period is being increasingly targeted for secondary prevention trials
of new therapies. In this context, the interest of a noninvasive, cost-effective amyloid-! (A!) blood-based test does not need
to be overstated. Nevertheless, a thorough validation of these bioanalytical methods should be performed as a prerequisite for
confident interpretation of clinical results. The aim of this study was to validate ELISA sandwich colorimetric ABtest40 and
ABtest42 for the quantification of A!40 and A!42 in human plasma. The validation parameters assessed included precision,
accuracy, sensitivity, specificity, recovery, and dilution linearity. ABtest40 and ABtest42 proved to be specific for their target
peptide using A! peptides with sequence similar to the target. Mean relative error in the quantification was found to be below
7.5% for both assays, with high intra-assay, inter-assay, and inter-batch precision (CV <9.0% on average). Sensitivity was
assessed by determination of the limit of quantification fulfilling precision and accuracy criteria; it was established at 7.60
pg/ml and 3.60 pg/ml for ABtest40 and ABtest42, respectively. Plasma dilution linearity was demonstrated in PBS; however,
dilution in a proprietary formulated buffer significantly increased the recovery of both A!40 and A!42 masked by matrix
interactions, allowing a more comprehensive assessment of the free and total peptide levels in the plasma. In conclusion,
both assays were successfully validated as tools for the quantification A!40 and A!42 in plasma.
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INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative
disorder characterized by the extracellular deposi-
tion of amyloid-! (A!) in cerebral A! plaques and
the formation of intracellular neurofibrillary tangles
in the brain [1]. A definite diagnosis of AD, which
currently affects 46.8 million people worldwide [2],
can only be established by postmortem evaluation
of these two pathological hallmarks of the disease
[3]. Nevertheless, recent advances in neuroimaging
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and cerebrospinal fluid (CSF) biomarker assays have
led to a new paradigm for the disease and have pro-
vided tools to identify the disease in vivo. The new
paradigm considers a long preclinical stage during
which AD pathologies are developing prior to the
onset of clinical symptoms [4–6]. This preclinical
period is being increasingly targeted for secondary
prevention clinical trials of new therapies aimed to
delay or avoid the apparition of incapacitating demen-
tia symptoms. Since, by definition, preclinical AD
cannot be detected by clinical measures, biomarkers
are needed to identify individuals in this important
stage of the disease in order to enrich cohorts for clin-
ical trials with people at increased risk of developing
the disease and eventually, when disease-modifying
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drugs become available, for management of patient
treatment. Among them, A! biomarkers, measured
either by increased accumulation of A! peptides in
brain or A!42 reduction in CSF, have demonstrated
their utility as preclinical biomarkers of AD [7–14].
A! species are also measurable in peripheral
blood and mounting evidence shows that plasma A!
peptide levels are associated with the risk of dis-
ease progression, brain A! levels, or other markers
of neurodegeneration such as structural brain atro-
phy determined by MRI [15–20]. Nevertheless, the
strength of this association remains to be definitively
established, which will determine the potential utility
of A! blood-based assays with regard to the diagnosis
of AD.
The advantages of a blood-based test as a
cost-effective non-invasive tool for clinical trial
enrichment and population screening do not need to
be stressed [21]. In fact, it has been proposed that
blood-based methods could serve as the first step in a
multistep diagnostic process [22]. With this in mind,
together with special attention to pre-assay aspects,
a thorough validation of the bioanalytical method
should be performed to define performance charac-
teristics as a prerequisite for confident interpretation
of clinical results.
The quantification of these peptides at the low level
in which they are found in plasma and the notori-
ous difficultly associated with their handling could
explain contradictory results to date and some past
controversies. The hydrophobic nature of A! pep-
tides makes them difficult to analyze due to their
propensity to bind with plasma proteins such as albu-
min,"2-macroglobulin, lipoproteins, or transthyretin
[23–26]. These interactions are likely to cause epi-
tope masking, preventing the A! peptides from being
detected in an immunoassay. These physicochemical
features of A! are related to other sources of variabil-
ity in their determination, attributable to differences
in pre-analytical and analytical procedures [27–30].
The present study reports the validation results of
two specific tools, ABtest40 and ABtest42, devel-
oped by Araclon Biotech Ltd. for the quantification
of both free and total A!40 and A!42 in plasma. The
free A! in plasma (FP) fraction corresponds to the
amount of those peptides that are readily available
for immunoassay detection. Total A! in plasma (TP)
refers to the amount of these peptides that can be
measured after pre-treating the plasma sample with
a formulated buffer that breaks the interactions of
the peptide with other plasma components (mostly
proteins), which could be masking up to 50% of the
peptide in the sample [31]. To the extent possible,
regulatory guidelines for validation of bioanalytical
methods [32, 33] were followed to conduct exper-
imental designs and a priori establish acceptance
criteria, as well as other recommendation papers
focused on this specific field [34].
MATERIAL AND METHODS
Assay description and procedure
ABtest40 and ABtest42 (Araclon Biotech Ltd.
Zaragoza, Spain) are two colorimetric tests based
in the sandwich enzyme-linked immunosorbent
assay (ELISA) technique as described elsewhere
[31]. Briefly, a monoclonal antibody (1F3, Araclon
Biotech) specific to the N-terminal fragment of A!
and immobilized in a microplate well, reacts with
A! species during an overnight incubation at 2–8◦C.
Dilution of both standards and samples is always per-
formed in Sample/Standard Diluent. After a 5-cycle
washing step to remove any non-specific binding, the
immobilized peptides are detected by the addition of
a biotinylated polyclonal antibody, also developed
by Araclon Biotech, specific of the C-terminal end
of either A!40 (pAB002) or A!42 (pAB031). The
detection reaction is carried out during 1 h at room
temperature and shaking (30 rpm 3D orbital shaking).
After repeating the washing step, a streptavidin-HRP
amplification reaction takes place (1 h, room temper-
ature, shaking), followed by a washing cycle and a
colorimetric reaction during 30 min in the dark with
a chromogen substrate, TMB. Analyte concentration
is proportional to optical density at 450 nm.
The pair of antibodies implied in each assay are
developed and produced by Araclon Biotech. Poly-
clonal antibodies are purified by antigen-affinity
chromatography using the same A! fragment inoc-
ulated to the rabbits. The monoclonal antibody is
purified by class-specific affinity using protein-G
columns. Each production batch is subjected to an
exhaustive quality control, including specificity and
sensitivity evaluation to ensure lot-to-lot consistency,
especially relevant when using polyclonal antibod-
ies. The stock of polyclonal antibody in the kit is
supplied at a batch-to-batch adjusted concentration
to keep inter-lot consistency.
The validation experiments were performed using
human plasma samples obtained from the Arago´n
Tissue and Blood Bank (Zaragoza, Spain) in accor-
dance with the Helsinki Declaration of 1975.
V. Pe´rez-Grijalba et al. / ABtest for the Quantification of A! in Plasma 753
Assay calibration
The standard calibration curve was prepared from
synthetic A!1-40 and A!1-42 peptides (Araclon
Biotech Ltd.). The amino acid sequence of both pep-
tides matches that from the complete corresponding
human peptide. The synthesis of both complete A!
species was carried out using Fmoc solid phase in
an automatic synthesizer (Applied Biosystems Inc.,
Foster City, CA, USA) and released from the resin
by a cleavage process. The A! peptides were puri-
fied by HPLC and their sequence was confirmed by
mass spectrometry (MALDI-TOF), ensuring in the
process, the purity and identity of the specific A!
peptide.
ABtest calibrators are prepared after a disaggrega-
tion procedure and resuspension of controlled-weight
lyophilized aliquots to 1 mg/ml in NH4OH 0.1%.
A first dilution step is carried out in guanidine
hydrochloride 6M to a concentration of 200#g/ml,
followed by serial dilutions in Sample/Standard Dilu-
ent to obtain the calibrator stock provided with the
kit. Quality control procedures, including mass spec-
trometry, HPLC and ELISA, are applied in-process
and after batch releasing, to ensure batch to batch con-
sistency. Each calibrator batch needs to fulfill quality
control criteria of accuracy (less than 10% signal
deviation at the maximum of quantification range)
with regard to three independent reference stocks of
the corresponding peptide. Additionally, ABtest cal-
ibrators must meet requirements of back-calculated
concentration accuracy (less than 20% bias at each
calibration point, regarding the theoretical concentra-
tion), as well as goodness of fit in a routine calibration
curve procedure.
Calibrators for ABtest40 and ABtest42 were
diluted 1/100 in Sample/Standard Diluent. Then,
serial dilutions were carried out to obtain the 7 lev-
els of concentration of the standard curve, reducing
half the concentration in each step. In each assay, a
calibration curve was assayed in duplicate and plot-
ted using a 4-parameter logistic regression with a 1/y
weighting variable, using the Gen5 software (BioTek
Instruments, Inc., Winooski, VT, USA).
To validate the dynamic range of the assay that
goes from 3.125 to 200 pg/ml for both ABtest, each
standard level should meet precision and accuracy
criteria. The coefficients of variation (CV) of the cal-
ibrator duplicates should be≤20%, except for the
lowest calibrator for which CV≤25% is accepted.
Back-calculated concentrations for calibrators should
be± 20% of the theoretical for acceptance (±25%
for the lowest standard). To assess the suitability of
the calibration method, 6 runs of the standard curve
were prepared independently in each assay from dif-
ferent aliquots of the same calibrator batch, both with
ABtest40 and ABtest42.
Analytical specificity
The specificity of both assays was evaluated by
analyzing different A! peptides with a sequence sim-
ilar to the target peptide. Serially truncated sequences
of A!, both in C- and N-terminal, were assayed
at the highest concentration of the dynamic range
of the test (200 pg/ml). Investigation of the speci-
ficity in N-terminal was performed in ABtest40 (same
results were expected for ABtest42 since they share
the same capture antibody) with A!2-40, A!3-40,
[Pyr3]A!3-40, A!4-40, A!11-40, and murine A!1-40
(AnaSpec, Inc., Fremont, CA, USA). Specificity in
C-terminal was evaluated with the truncated species
A!1-37 (Bachem, Budendorf, Switzerland), A!1-38
(Araclon Biotech Ltd., Zaragoza, Spain) and A!1-43
(AnaSpec), besides A!40 or A!42 depending on the
ABtest used.
Specificity was established as the percentage of
cross reactivity of the truncated species regarding the
target A! peptide signal.
Limit of quantification
The limit of quantification (LoQ) of both ABtest
assays was established following the guidelines
included in the Clinical & Laboratory Standards Insti-
tute (CLSI) guidelines [35]. First, the limit of blank
(LoB) was estimated by repeated determination of
four plasma samples without A!40 or A!42 using
three different batches of ABtest40 and ABtest42, in
three runs with six replicates per assay. The deple-
tion of plasma was carried out after incubation of the
samples in a solid phase conjugated with 1F3, the
specific anti N-terminal A! antibody. The apparent
concentration of A!40 or A!42 in these A! depleted
samples was determined for each replicate and the
concentration corresponding to the LoB was estab-
lished following the procedure proposed by CLSI
[35].
LoB = µB + CpSDB
where #B is the mean apparent concentration
and SDB the standard deviation; Cp (for a set "
error of5 % ) = 1.6451−(1/(4(B−K)) being B the number of
replicates and K the number of samples.
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Following this, the limit of detection (LoD) of
ABtest40 and ABtest42 was estimated by analyz-
ing four samples with a concentration of A!40 or
A!42 close to the LoB previously established. Quan-
tification of these samples was repeated in three
different assays including six replicates in each run.
This experimental design was performed with three
different batches of ABtest40 and ABtest42 and LoD
was determined following the guidelines proposed in
EP17-A2 report [35]
LoD = LoB + CpSDL
Where SDL =
√∑J
i=1 (ni − 1) SD21∑J
i=1(ni − 1)
;
Cp ("= 5%) = 1.6451 − (1/ (4 (L − J)) ,
being L the number of replicates and J the number of
samples assayed.
Finally, the limit of quantification (LoQ) of the
assay was established as the lowest A!40 or A!42
concentration above the LoD which can be deter-
mined with precision and accuracy. In this sense,
samples with progressively increased concentration
of A!40 or A!42 from LoD were assayed in 44 repli-
cates with two batches of ABtest40 or ABtest42,
respectively. The lowest concentration that meets the
criteria of precision (CV≤ 25%) and accuracy (RE≤
25%) was established as the LoQ of the assay.
Precision
To evaluate precision, five plasma samples with
A!40 or A!42 levels covering the whole dynamic
range of the assay were prepared so that repro-
ducibility was guaranteed independent of the A!
concentration. When it was not possible to find natu-
ral samples at a particular concentration level, they
were partially depleted as previously described or
artificially enriched with the corresponding synthetic
peptide by spiking A!40 or A!42.
Precision of ABtest40 and ABtest42 was assessed
at different levels. Intra and inter-assay reproducibil-
ity was examined by quantifying the same five
samples as replicates (n = 6) in the same run and in six
different and independent runs, both with ABtest40
and ABtest42. Inter-batch precision was assessed
comparing the concentration obtained in each of these
five samples with three different batches of ABtest40
or ABtest42, in three independent runs.
Precision was determined by calculating the CV
of the different measurements of the same sample
carried out in the same run, among different runs
and among different ABtest batches. The accep-
tance criterion was established as a CV≤20%, with
the exception of the sample close to the lower
limit of quantification (LLOQ) of the assay where
a CV≤25% is allowed.
Accuracy
ABtest40 and ABtest42 accuracy was also evalu-
ated in the whole dynamic range of the assay with the
same five samples described in precision assessment.
Firstly, the A!40 and A!42 theoretical concentration
in these samples was determined by repeated quan-
tification including all the factors that could affect
the assay: six replicates of each sample in four inde-
pendent runs with two different batches of either
ABtest40 or ABtest42 (total quantifications of each
sample = 48).
Once the theoretical concentration of A!40 and
A!42 was determined, the accuracy assessment
implied the quantification of these five samples with
a different batch of ABtest40 or ABtest42 in six dif-
ferent runs with six replicates of each sample per run
(n = 36). The accuracy was established in terms of
the relative error (RE), i.e., the percentage of the
difference between an observed concentration and
the theoretical concentration divided by the theoreti-
cal concentration. Mean RE was calculated for each
concentration level (taking the absolute values) and
the acceptance limit established at RE≤20% (except
LLOQ, where RE≤25%).
Analyte spike recovery
The effect of the plasma matrix in the recovery of
synthetic A! peptides was investigated. A!1-40 and
A!1-42 standards were added to undiluted plasma
and to plasma after three-fold dilution in Sam-
ple/Standard Diluent, which is the dilution usually
carried out for analysis. To study the recovery in the
whole range of the assay, three A!40 and A!42 con-
centrations (150 pg/ml, 75 pg/ml, and 20 pg/ml) were
added to three different plasma samples and repeated
in three different runs. The volume of A! peptides
added to the samples never exceeded 5% of the final
sample volume, in order to minimize matrix alteration
while keeping pipetting accuracy in the procedure.
Samples were assayed with ABtest within 30 min
after spiking. Every step was carried out at room
temperature.
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The matrix effect in these samples was evalu-
ated by calculating the percentage of recovery of the
known concentration of A! added, as an average of
the three individuals and assays.
Dilution linearity
Five different plasma samples were serially diluted
three, six, and nine times either in the assay’s Sam-
ple/Standard Diluent or in a saline buffer as PBS,
in parallel with both buffers and always in dupli-
cate. The linearity of the association was assessed
graphically by plotting either the signal or concentra-
tion obtained versus the inverse of the corresponding
dilution factor.
Statistical treatment
The parameters studied in each validation step
were included as summary descriptive statistics
where the mean and range estimates were calculated.
Descriptive statistics included the calculation of
mean, range, standard deviation (SD), CV, RE, and
percentage of recovery.
RESULTS
The main results obtained in the validation assays
of ABtest40 and ABtest42 are summarized in Table 1,
both for ABtest40 and ABtest42.
Assay calibration
The calibration range was selected taking into
account the expected levels of A!40 and A!42 in
plasma. A quantification range from 3.125 pg/ml to
200 pg/ml was evaluated to accomplish the precision
and accuracy goals. All the calibration levels ful-
filled the acceptance criteria previously established
with a mean RE of 4.5% for ABtest40 and 2.9%
for ABtest42. On average, the variability (CV) of all
the concentration replicates of the calibration curve
was 5.2% and 4.2% for ABtest40 and ABtest42,
respectively. The RE and CV values obtained at each
calibrator level in the six runs performed are summa-
rized in Supplementary Table 1.
Analytical specificity
The anti-A! N-terminal antibody, shared by
ABtest40 and ABtest42, did not show any signifi-
cant (lower than 4%) cross reactivity with A! species
starting at amino acid 4 and subsequent amino acids
or with murine A! (see Supplementary Table 2). The
antibody 1F3 is reactive to A! peptides containing at
least amino acid 3 of the A! sequence, even when it is
modified as with the pyroglutamate in [Pyr3]A!3-40,
i.e., it is reactive 100% to A!1-40, and above 96% for
A!2-40, A!3-40, and [Pyr3]A!3-40.
ABtest40 was completely specific for the target
A!40 peptide with cross reactivity of similar species
(A!1-37, A!1-38, A!1-42, and A!1-43) below 2% in
all cases. Similarly, ABtest42 showed high speci-
ficity for A!42, without recognizing A!1-37, A!1-38,
A!1-40, or A!1-43; the signal percentage of these
species regarding the target A!42 was below 5% in
all cases (results shown in Supplementary Table 2).
Limit of quantification
After determining the LoD (see Supplementary
Table 3), the lowest concentration empirically tested
for precision and accuracy was 7.60 pg/ml for
ABtest40 and 3.60 pg/ml for ABtest42. Both con-
centrations proved to be accurate (RE of 3.4% for
ABtest40 and 16.8% for ABtest42) and precise (CV
of 21.6% for ABtest40 and 18.1% for ABtest42),
confirmed in one run with 44 replicates, using two
different batches of each ABtest (see Supplementary
Table 4). Therefore, the limit of quantification was
established in 7.60 pg/ml for ABtest40 and 3.60 pg/ml
for ABtest42.
Precision
For a given plasma sample, the variability between
concentrations determined in the same assay, in dif-
ferent assays and with different ABtest batches was
always below 15% (Fig. 1). Both ABtest40 and
ABtest42 demonstrated good reproducibility when
analyzing samples in the same assay with a mean
CV of 5.8% for ABtest40 and 5.4% for ABtest42.
The inter-assay variability was found to be 7.7%
and 7.5%, respectively, for ABtest40 and ABtest42,
as an average of the five concentration levels stud-
ied. The same five samples were analyzed in parallel
with three different ABtest batches, with a mean CV
of 4.8% for A!40 and 8.8% for A!42 quantification
(Supplementary Figure 1).
Accuracy
Accuracy was evaluated in each concentration
level by the relative difference between each deter-
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Table 1
Summary of validation results for ABtest40 and ABtest42 quantification of A!40 and A!42 in plasma
Validation parameter ABtest40 ABtest42
Mean Range Mean Range
Calibration Quantification range (pg/ml) 3.125 to 200 pg/ml 3.125 to 200 pg/ml
Accuracy, RE (%) 4.5 –17.2 to 12.4 2.9 –12.4 to 8.4
Precision, CV (%) 5.2 0.5 to 11.7 4.2 0.2 to 19.7
Precision Intra-assay, CV (%) 5.8 3.9 to 12.0 5.4 3.8 to 7.9
Inter-assay, CV (%) 7.7 3.6 to 15.0 7.5 4.6 to 11.0
Inter-batch, CV (%) 4.8 3.2 to 6.2 8.8 5.1 to 13.5
Accuracy 7.2 –17.8 to 32.1 7.1 –35.2 to 28.4
Spike recovery Undiluted plasma, recovery (%) 60.4 39.9 to 82.7 63.6 53.6 to 85.4
Diluted plasma, recovery (%) 96.0 82.1 to 122.0 94.9 81.9 to 125.2
Specificity Cross-reactivity (%) 0.0 to 1.4% 0.8 to 4.1%
Sensitivity Limit of quantification (pg/ml) 7.60 3.60
RE, relative error; CV, coefficient of variation. The calibration method was evaluated in terms of accuracy (with the back-calculated calibrator
concentration) and precision of the calibrator duplicates.
Fig. 1. Precision parameters for ABtest40 and ABtest42. Intra-assay (A), inter-assay (B), and inter-batch (C) mean variability for each
concentration level studied. CV, coefficient of variation. LLOQ (concentration close to the lower limit of quantification of the dynamic range
of the assay): 16.09 pg/ml A!40, 18.84 pg/ml A!42. LOW: 30.01 pg/ml A!40, 26.89 pg/ml A!42. MID (middle concentration): 53.44 pg/ml
A!40, 55.96 pg/ml A!42. HIGH: 113.55 pg/ml A!40, 89.16 pg/ml A!42. ULOQ (concentration close to the upper limit of quantification of
the dynamic range): 191.91 pg/ml A!40, 162.35 pg/ml A!42.
mination carried out (n = 36 for each concentration
level) and the theoretical concentration of A!40 or
A!42 previously determined for each sample. In
Fig. 2, the RE obtained for each determination is
plotted regarding each concentration level. Mean RE
values are summarized in Supplementary Table 5,
with an average accuracy for ABtest40 of 7.2% and
7.1% for ABtest42.
Analyte spike recovery
The mean recovery percentage of A! spiked in
undiluted plasma was 60.4% for A!40 and 63.6%
for A!42, whereas it rose up to 94.0–95.0% for both
A!40 and A!42 peptides from the three-fold dilu-
tion of plasma in Sample/Standard Diluent. Recovery
was constant for the different concentration levels
added to the samples, and did not differ significantly
among different individuals (n = 3, see Supplemen-
tary Table 6).
Dilution linearity
The signal obtained after serially diluting a plasma
sample in PBS follows a linear tendency to decline
(Fig. 3). In contrast, the dilution of the same sam-
ples in Sample/Standard Diluent provided a nonlinear
association since the signal drop, especially with
a 3-fold dilution, was smaller than expected for a
linear association and comparing to the PBS dilu-
tion (Fig. 3A, B). Consequently, the maximum A!
concentration measured in each of the 5 samples
assayed was obtained when they were diluted 1/3 in
Sample/Standard Diluent (Fig. 3C, D). See further
information in Supplementary Table 7.
DISCUSSION
The ELISA technique is frequently used for mea-
surement of low-abundance biomarkers. However,
the quality of ELISA methods varies, which may
introduce both systematic and random errors. The
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Fig. 2. Accuracy in the quantification with ABtest40 and ABtest42. Each point represents the relative error (RE) in percentage in each of the
36 determinations carried out at each concentration level regarding the theoretical concentration of the plasma sample. LLOQ: concentration
close to the lower limit of quantification of the dynamic range of the assay. MID: middle concentration. ULOQ: concentration close to the
upper limit of quantification of the dynamic range.
Fig. 3. Dilution linearity of ABtest40 and ABtest42. Linearity was evaluated by three-, six- and nine-fold serial dilution from five undiluted
plasma samples, either in a standard saline buffer as PBS or in Sample/Standard Diluent. Panels A and B represent the association of the
signal obtained with respect to the dilution performed for A!40 and A!42, respectively. Panels C and D show the association of the corrected
concentration (after applying the corresponding dilution factor) obtained with regard to dilution, for A!40 and A!42, respectively. Each point
represents the mean response or concentration obtained for the five samples. Bars represent the standard mean error.
aim of this study was to assess the performance
of ABtest40 and ABtest42 in terms of specificity,
sensitivity, precision, and accuracy, including an
evaluation of the matrix effect and a validation of
the calibration method. Regarding the later, a 4-
parameter weighted logistic regression demonstrated
good precision and accuracy in the whole dynamic
range of the assay, allowing a non-biased quantifica-
tion from the sample signal obtained.
The specificity tests confirmed the complete lack
of recognition of A!42 by ABtest40 and of A!40 by
ABtest42, which guarantees that only the target A!
form is being recognized in each case. Moreover,
no other C-terminal truncated A! peptides, either
shorter or longer than the specific A!, produced
any signal in the test, providing robustness to the
quantification. This may be relevant given the promis-
ing value as an AD biomarker of the ratio A!42/40
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suggested in previous studies [15–18]. Specificity
in N-terminal, shared by ABtest40 and ABtest42,
showed that at least the presence of amino acid 3
(glutamic), even modified as pyro-glutamic, is needed
for the recognition of A!. Therefore, ABtest40 and
ABtest42 are reactive for the full-length A!1-40/42
as well as the N-terminal truncated forms A!2-40/42,
A!3-40/42, and [Pyr3]A!3-40/42, and do not recog-
nize further truncated species in N-terminal. Hence,
the final A! concentration provided by these tests
will include the aforementioned forms of the A! pep-
tide. The recognition of the cycled form of A!3-x
could be of potential interest since there is some evi-
dence showing this species as an important part of
the pathological process of AD implied in aggrega-
tion processes [36, 37]. A remarkably higher signal
for the A! form A!3-40 compared to the other specific
peptides was observed. Although remarkable, this
finding has limited relevance concerning the speci-
ficity of the capture antibody and most probably is
not due to a higher reactivity to this A! species. In
our opinion, this could be explained by differences
in the concentration accuracy from commercial pep-
tides since, in some cases, the counterion effect is
not reflected in the amount of peptide declared. On
the other hand, ABtest40 and ABtest42 are species
specific and do not recognize the murine form of A!,
which could be useful for possible use in studies with
transgenic mice.
Sensitivity was evaluated following an exigent pro-
cedure in sequential and confirmatory steps, to ensure
that the lowest concentration, which can be reliably
quantified with ABtest40 and ABtest42, truly cor-
responds to that obtained empirically in this study.
The lowest A! concentration that can be quantified
with precision and accuracy was 7.60 pg/ml for A!40
and 3.60 pg/ml for A!42. Both limits of quantifi-
cation are adequate for the existing levels of A! in
plasma.
Precision and accuracy were thoroughly assessed
with five samples spanning the dynamic range of the
assay. Regarding the precision results, variability was
always far below the standard acceptance criteria, for
each concentration level and for intra and inter-assay
as well as inter-batch determinations, with a mean
global precision of 6.1% for ABtest40 and 7.2% for
ABtest42. Although these precision levels are more
than acceptable and similar to other A! quantification
methods more experienced in clinical practice appli-
cation, as CSF analysis [38], it is still a key point
affecting robustness of the measurements. Consid-
ering the significant lower levels of A! in plasma
regarding CSF, precision is even a more critical fea-
ture for a blood-based test.
Concerning accuracy evaluation, only one in 36
A!40 determinations was out of the acceptance range
(32.0% RE in LLOQ). For ABtest42, 3 determina-
tions at LLOQ showed a RE above 25% (26.6%,
30.5%, and 35.2%). For the other four concentration
levels as a whole, a RE slightly over 20% was found
in five cases, but below 28% in all cases. Apart from
these unusual biased determinations, both ABtest40
and ABtest42 showed good accuracy in quantifica-
tion, being that the average relative error obtained
was about 7%. Consequently, precision and accuracy
in the quantification of A!40 and A!42 were con-
firmed to be within the a priori established acceptance
criteria along the whole dynamic range of the assay
and in accordance with other tests results [39–43].
Recovery tests demonstrated a matrix effect in the
plasma sample that was preventing ABtest40 and
ABtest42 from quantifying 40–45% of the peptide
present in the untreated sample, as shown by a recov-
ery limited to a 60–65% of the A!40 and A!42
added to the undiluted plasma sample. Neverthe-
less, the adequate dilution (1/3) of the plasma sample
in an appropriate buffer (Sample/Standard Diluent)
increased recovery to more than 90%, demonstrat-
ing a substantial removal of the interference in the
plasma matrix. The 3-fold dilution was selected from
previous results evaluating a whole range of dilution
factors as it provided the best recovery results. Inter-
estingly, linearity assays corroborate this effect by
the Sample/Standard Diluent observed in the recov-
ery evaluation. Thus, serial dilution of neat plasma
in a standard saline buffer such as PBS yielded a
linear association of signal regarding the dilution car-
ried out. However, the parallel dilution of the same
plasma samples in Sample/Standard Diluent pro-
duced a signal drop unexpectedly much smaller than
that caused by PBS dilution, especially at a 3-fold
dilution (Fig. 3). As a consequence, the 3-fold dilu-
tion of plasma in Sample/Standard Diluent provided
the maximum A! that can be quantified both with
ABtest40 and ABtest42, giving a determination with
biological meaning itself as the total amount of A!
present in the sample that can be determined in this
immunoassay. Other assays developed for the quan-
tification of A! species in plasma dilute the plasma
matrix in detergent based diluents [44], even find-
ing a maximum signal at 1/3 dilution of plasma [42].
However, many publications dealing with A! blood-
based test do not report any pre-dilution of the plasma
samples [15, 45, 46], which should be considered an
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important factor to be standardized and taken into
account for a comprehensive quantification of A! in
plasma.
These results support the hypothesis that the for-
mulated Sample/Standard Diluent has a specific and
active influence over the interactions of A!with other
plasma components that are well described in the
bibliography [23–26, 47]. Thus, the dilution in Sam-
ple/Standard Diluent goes beyond what is expected
for the dilution of a biological matrix, as can be seen
compared to PBS; its specific formulation is releas-
ing A! previously bound to plasma components and
not accessible for its quantification by ELISA in
the undiluted sample. Consequently, quantification
of A! in an undiluted plasma matrix includes only
the peptide that is directly accessible to be measured
(or that is not interacting with masking components)
whereas assaying the plasma sample diluted 1/3 in
Sample/Standard Diluent allows for the determina-
tion of the total quantifiable A! after recovering the
peptide masked by these interactions.
Blood-based tests for the diagnosis of AD are
still in a discovery phase and in these initial stages
a more comprehensive assessment of the concen-
tration and distribution of A! in the plasma may
afford an incremental benefit compared with single
snapshot determinations, which are affected by the
complex interaction of A! peptides with the individ-
uals’ plasma matrix. Previous results in pilot studies
support the idea that this comprehensive approach
might help to develop blood-based tests into useful
tools for the screening of people at increased risk of
developing AD and warrant additional research in this
area [48–50].
ABtest40 and ABtest42 have proved to be robust
and reliable tools for quantification of A!40 and A!42
in plasma and this study provides important infor-
mation about the quantitative performance expected
from them which is relevant as there is an urgent need
for an early and easily accessible AD biomarker and
many studies have been carried out to explore the
association between plasma A! and AD, although
with contradictory results [16, 43, 46, 51–57]. We
believe that part of this controversy could be due
to the lack of standardization and validation of the
plasma A! determination, which raises numerous
issues that may impact upon the reproducibility
of results. Diverse assay methodologies, antibodies
produced under different conditions and/or from dif-
ferent sources and varied detection techniques can
result in different outcomes and performance (see
Supplementary Table 8). The variation in detectable
levels of A! could also likely be produced by the
use of different diluents and/or dilution factor in the
assay [42]. Together with these analytical-phase fac-
tors, the importance of standardizing pre-analytical
factors such as sample collection procedures, sam-
ple storage and pre-assay preparation for reliable
and reproducible AD biomarker measurements has
been highlighted previously [27, 29, 58–60]. The
aforementioned issues reinforce the reason why a
validation of any quantitative tool is mandatory.
The limitations of this validation study comprise
the lack of stability assessment of samples (both
long-term stability and freeze-thaw cycles effect) and
of some kit’s components. It is also important to
evaluate the reproducibility of the quantification in
different laboratories, since it has been shown to be
a critical aspect in the evaluation of other A! assays
[29]. In agreement with this and to keep under con-
trol this important source of variability, ABtest is
currently being provided as a service by a refer-
ence laboratory. Additionally, no clinical data have
been included in this work; the clinical utility of
ABtest is already under evaluation in independent
studies with well-defined cohorts, and the corre-
sponding manuscripts are in preparation. Besides
these aspects, other sample-related potential factors
that could affect A! determination, such as creatinine
or total protein levels, should be evaluated to confirm
the robustness of the test in clinical settings.
In conclusion, ABtest40 and ABtest42 have proven
to be specific, sensitive, precise and accurate enough
to quantify A!40 and A!42 at the levels existing in
plasma. This validation gives reliability to any quan-
tification with ABtest in a clinical trial environment,
which brings to light its capabilities as a cost-effective
tool for the determination of potential AD biomarkers
in plasma. So far, A!40 and A!42 determinations in
plasma, although of great scientific interest, have not
been validated as a diagnostic tool in clinical settings.
Hence, the next step should be the evaluation of the
clinical utility of these measurements to validate the
intended use of ABtest. Regarding this objective, sev-
eral studies in consolidated and well-characterized
populations are already being carried out.
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